Fulcrum Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €41.54M +112.0% -€42.66M -37.2% -102.7% +2.4 pp N/A N/A
    (estimated) €19.59M +∞% -€67.93M -1.0% -346.7% -3.5 pp N/A N/A
    (estimated) €0.00 +NaN% -€68.61M -0.8% N/A N/A N/A
    (estimated) €0.00 +NaN% -€69.18M +12.8% N/A N/A N/A
    (estimated) €0.00 -100.0% -€61.34M +632.1% N/A N/A N/A
    €68.92M +2,752.0% -€8.38M -90.0% -12.2% +35 pp -€1.67M -97.9% -2.4% +32 pp
    €2.42M -55.8% -€83.86M -7.8% -3,470.1% -18 pp -€77.93M -4.9% -3,224.8% -17 pp
    €5.46M -66.9% -€91.00M +34.8% -1,665.4% -13 pp -€81.92M +23.9% -1,499.3% -11 pp
    €16.51M +117.2% -€67.49M +14.5% -408.8% +3.7 pp -€66.14M +46.7% -400.6% +1.9 pp
    €7.60M +∞% -€58.96M -13.5% -775.7% -7.8 pp -€45.07M +35.4% -592.9% -5.9 pp
    €0.00 +NaN% -€68.16M +142.8% N/A -€33.28M +184.4% N/A
    €0.00 +NaN% -€28.08M +41.9% N/A -€11.70M -25.2% N/A
    €0.00 -€19.78M N/A -€15.65M N/A

    Notifications